<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380938</url>
  </required_header>
  <id_info>
    <org_study_id>EPAT-01-2010</org_study_id>
    <nct_id>NCT01380938</nct_id>
  </id_info>
  <brief_title>Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)</brief_title>
  <acronym>WRITE</acronym>
  <official_title>RCT Comparing Different Ribavirin Dosages and Durations of Treatment in Combination With Peginterferon in HCV Genotypes 2 and 3 (WRITE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Casa Sollievo della Sofferenza IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Casa di Cura Mater Dei</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS L. Spallanzani</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Francesco Ferrari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero Universitaria di Sassari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arcispedale S. Anna, Ferrara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero-Universitaria, Catania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale di Venosa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale R. Dimiccoli, Barletta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS De Bellis, Castellana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>USL Napoli 1</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale San Giuseppe Moscati, Avellino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardarelli Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Civile Vittorio Emanuele II, Bisceglie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero-Universitaria Careggi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera V. Cervello</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Civile Spirito Santo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale di Canosa di Puglia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Palermo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Camillo Hospital, Rome</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Sandro Pertini, Roma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedali Riuniti di Foggia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale SS. Annunziata, Taranto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale di Mottola</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Santa Caterina Novella, Galatina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Valduce, Como</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera, Siracusa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera, Lucca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Casa Sollievo della Sofferenza IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      WRITE study aim at identifying the effectiveness of an innovative individualized schedule of
      treatment as compared to standard regimen in patients with chronic HCV genotype 2 and 3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are going to compare weight-based dosages of ribavirin, in combination with
      Peginterferon alpha-2a, with standard fixed dosages of 800 mg. Patients will be evaluated at
      week 4 with an assay of sensitivity of 15 IU/ml. Patients with week 4 response will
      discontinue treatment at week 12 in both arms. Patients with HCV RNA still detectable at week
      4 and receiving 1000-1200 mg of ribavirin in arm A will discontinue treatment at week 24,
      whereas patients with HCV RNA still detectable at week 4 and receiving 800 mg of ribavirin in
      arm B will be treated till week 48.

      A standard treatment arm (C) including patients treated for 24 weeks with Peginterferon
      alpha-2a and fixed 800 mg ribavirin dosage will be used as control arm.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological Response (SVR)</measure>
    <time_frame>6 months after the end of treatment</time_frame>
    <description>The primary measure of efficacy will be HCV RNA not detectable in serum samples 24 weeks after the end of therapy (SVR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rapid virological response (RVR)</measure>
    <time_frame>On treatment week 4</time_frame>
    <description>proportion of patients with undetectable HCV RNA 4 weeks after the start of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1150</enrollment>
  <condition>Chronic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Arm C. Standard duration</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be randomly assigned in 3:3:1 ratio to three treatment arms. In the standard treatment group (Arm C), patients will be treated for 24 weeks independently of the HCV RNA status at week 4 with Peginterferon alpha-2a at a dose of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.
Patients enrolled in Arm C will be treated for standard 24 weeks duration of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in Arm A will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 1000 mg/day for patients with a body weight &lt; 75 kg or 1200 mg/day for those with a body weight &gt; 75 kg.
Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm A), whereas those without RVR will be treated for 24 weeks (Arm A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in Arm B will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.
Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm B), whereas those without RVR will be treated for 48 weeks (Arm B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alpha-2a + Ribavirin</intervention_name>
    <description>Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight &lt; or &gt; 75 kg for 24 weeks (Arm A).
Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).
These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Peginterferon alpha-2a (40 kD) PEGASYS</other_name>
    <other_name>Copegus or Rebetol, Ribavirin Teva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic hepatitis C virus (HCV) infection (both HCVAb and HCV RNA
             positive)

          -  Patients with HCV genotype 2 or 3

          -  Age 18-70 years

          -  Naïve patients or previously treated only with standard interferon monotherapy

          -  Female patients of childbearing age who agree to avoid pregnancy during the period of
             treatment and 24 weeks after the end of treatment

        Exclusion Criteria:

          -  Previous treatment with ribavirin

          -  Cirrhosis (CHILD PUGH B and C)

          -  Evidence of Hepatocellular carcinoma

          -  Pregnancy

          -  Retinopathy class I or II

          -  Alcohol consumption &gt; 40 gr/day

          -  Chronic cardiac or respiratory diseases

          -  HIV or HBsAg or HDV positivity

          -  Hemoglobin &lt; 8.5 gr/dL

          -  WBC &lt; 3.500/mm3

          -  PLT &lt; 80.000/mm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra Mangia, MD</last_name>
    <role>Study Director</role>
    <affiliation>IRCCS &quot;Casa Sollievo della Sofferenza&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandra Mangia, MD</last_name>
    <phone>+39-0882-416270</phone>
    <email>a.mangia@operapadrepio.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Infectious Diseases Unit</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore D'Angelo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Unit</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Maio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Medicine Unit &quot;Mater Dei&quot;</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Agostinacchio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Dammacco, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medicine Unit</name>
      <address>
        <city>Barletta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Cuccorese, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Unit &quot;V. Emanuele&quot;</name>
      <address>
        <city>Bisceglie</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruggiero Francavilla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medicine Unit</name>
      <address>
        <city>Canosa di Puglia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Minerva, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hepatology Unit</name>
      <address>
        <city>Casarano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donato Bacca, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS &quot;De Bellis&quot;</name>
      <address>
        <city>Castellana</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Cozzolongo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hepatology Unit</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Russello, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Unit</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciano Nigro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Unit</name>
      <address>
        <city>Como</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giancarlo Spinzi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Unit Arcispedale &quot;S. Anna&quot;</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boccia Sergio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Unit</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Forte, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Medicine University of Firenze</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna L Zignego, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Unit</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Vinelli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaetano Scotto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Unit</name>
      <address>
        <city>Galatina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Tundo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases</name>
      <address>
        <city>Lucca</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sauro Luchi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Unit</name>
      <address>
        <city>Mottola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Termite, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Unit &quot;Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Di Costanzo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>USL Napoli 1</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Colucci, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;V. Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvo Madonia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Clinic University of Palermo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Montalto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Unit IRCCS &quot;San Matteo&quot;</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgio Barbarini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Campus Biomedico University</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Picardi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hepatology Unit &quot;S. Pertini&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Romano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hepatology Unit &quot;san Camillo&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriano Pellicelli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Villa Betania&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mecenate Fabrizio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS &quot;L. Spallanzani&quot;</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pasquale Narciso, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS &quot;Casa Sollievo della Sofferenza&quot;</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Mangia, MD</last_name>
      <phone>+39-0882-416270</phone>
      <email>a.mangia@operapadrepio.it</email>
    </contact>
    <contact_backup>
      <last_name>Leonardo Mottola, PhD</last_name>
      <phone>+39-0882-416271</phone>
      <email>leonardomottola@yahoo.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Unit Ospedale Civile</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Baudieri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medicine Unit</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Bandiera, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases</name>
      <address>
        <city>Siracusa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaetano Scifo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SS. Annunziata</name>
      <address>
        <city>Taranto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Sogari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medicine Unit</name>
      <address>
        <city>Venosa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vito Carretta, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Mangia A, Dalgard O, Minerva N, Verbaan H, Bacca D, Ring-Larsen H, Copetti M, Carretta V, Piazzolla V, Cozzolongo R, Mottola L, Andriulli A. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Aliment Pharmacol Ther. 2010 Jun;31(12):1346-53. doi: 10.1111/j.1365-2036.2010.04290.x. Epub 2010 Mar 8.</citation>
    <PMID>20222909</PMID>
  </reference>
  <reference>
    <citation>Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, Scotto G, Vinelli F, Ricci GL, Romano M, Carretta V, Petruzzellis D, Andriulli A. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology. 2009 Feb;49(2):358-63. doi: 10.1002/hep.22679.</citation>
    <PMID>19072829</PMID>
  </reference>
  <reference>
    <citation>Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 2008 Aug 15;28(4):397-404. doi: 10.1111/j.1365-2036.2008.03763.x. Epub 2008 Jun 11. Review.</citation>
    <PMID>18549461</PMID>
  </reference>
  <reference>
    <citation>Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005 Jun 23;352(25):2609-17.</citation>
    <PMID>15972867</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>April 14, 2012</last_update_submitted>
  <last_update_submitted_qc>April 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Casa Sollievo della Sofferenza IRCCS</investigator_affiliation>
    <investigator_full_name>Alessandra Mangia</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>genotypes 2 and 3</keyword>
  <keyword>combination treatment</keyword>
  <keyword>individualized treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

